Login

Recent searches

No recent searches

Search options

Not available on mastodon.xyz.
mastodon.xyz is one of the many independent Mastodon servers you can use to participate in the fediverse.
A Mastodon instance, open to everyone, but mainly English and French speaking.

Administered by:

Server stats:

824
active users

mastodon.xyz: AboutProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.3.4

#CovidIsNotOver

56 posts50 participants10 posts today
Public
Merlin Gillard 🚋😷

Et voilà les premiers signes d'une remontée de la circulation du Covid en #Belgique, après presque 3 mois de circulation à basse intensité...

➡️ Pour protéger les autres et vous éviter des risques de covid long ou autres complications après une infection:
😷 Portez un masque
🌬️ Aérez les pièces et allumez les détecteurs de CO2
ℹ️ + d'infos:
- associationarra.wordpress.com/
- autodefensesanitaire.fr/
- nousaerons.fr

Source du graphe: wastewater.sciensano.be/dashbo
#CovidIsNotOver

Graphique de la circulation du covid-19 dans les eaux usées en Belgique. Le graphique montre plusieurs vagues entre aout 2023 et fin mars 2025. Et particulièrement, entre novembre 2024 et mi-mars 2025, la courbe est à un niveau stable et relativement bas comparé au reste de la période. Mais cela change avec la dernière observation, qui remonte brusquement: sa valeur est le double de la valeur de l'avant-dernière observation.
Replied in thread
Public
datum (n=1)

@DenisCOVIDinfoguy they also cite pubmed.ncbi.nlm.nih.gov/358102

which has this absolute adjective of a hypothesis:

SARS-CoV-2 may bind to ACE2 in order to enter the host brainstem cell and change baroreflex sensitivity

because

The integral parts of the brain renin-angiotensin system, as ACE2 enzyme, are highly expressed in the brainstem, which may also be involved in baroreflex sensitivity, playing an important role in HRV.

which would help explain POTS!!

PubMedPotential autonomic nervous system dysfunction in COVID-19 patients detected by heart rate variability is a sign of SARS-CoV-2 neurotropic features - PubMedIncreasing evidence strongly support that the newly identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to the development of COVID-19-associated central nervous system (CNS) manifestations. The presence of SARS-CoV-2 viral protein in the brainstem, which includes cardiovas …
#COVID#COVID19#SARS2
Public
Tom Kindlon

Brain Structural Abnormalities in Patients with #PostCOVID -19 Headache

mdpi.com/2035-8377/17/4/50

Retrospective 30 vs 30 MRI case/control study. "One of our most noteworthy findings is that white matter lesions were identified in 50% of the post- #COVID-19 group, compared to 20% in the control group”

@longcovid
#LongCovid #PwLC #PostCovidSyndrome #LC #PASC #CovidBrain @covid19 #COVID19 #COVID #COVID_19 #SARSCoV2 #CovidIsNotOver #auscovid19 @auscovid19

Continued thread
Public
sport of sacred spherical cows

Updated #CDC estimates show we've pretty much been in a JN.1.11 soup since then, until late March, when LP.8.1 took majority.

Data collection continues to be a low priority nationally, as only one region (NY/NJ) has enough data for CDC to plot.

No new variants broken out, yet CDC seems to have resources to tailor their color key: hcommons.social/@beadsland/114

Raj's dashboard was updated on Sunday.

❖ #ThisIsOurPolio #Covid #Covid19 #SARS2 #variants #CovidIsNotOver #CovidIsAirborne #dataviz #datavis

Chart: Estimated U.S. Variant Proportions by Common Name Sources: Centers for Disease Control, CoV-Lineages, NYITCOM Research, Daniele Focosi, World Health Network, others [ beadsland on Ko-fi ] Reskin of CDC's Variants Nowcast, and any significant variants in GISAID not broken out by CDC. Five bar-style tree-charts, for fortnights through March 16–29. Legend of last fortnight, organized by subheadings of color-grouped families and convergent clusters. Percentages overlay each color key, reflecting share as of most recent tree-chart. Essentially all WHO-Vaccine-Target JN.1. LP.8.1 accounts for well over half; JN.1 + FLiRT for over a quarter. For fortnight of 3/2–3/15, packed bubble charts fill single-variant tiles, indicating diversification of those variants (per GISAID) that wouldn't otherwise be apparent from CDC's Nowcast. Legend: LP.8.1 [purple]: 55% - LP.8.1.1 / NY† & other LP.8.1 XEC [browns]: 21% - XEC.2† & other XEC 2% - XEC.4 JN.1.11 + FLuQE [greens]: 6% - MC.10.1 & MC.19 3% - MC.28.1 2% - XEQ 4% - MC.1 & other KP.3.1.1 / MC ⅘% - other KP.3 JN.1 + FLiRT [reds]: 4% - LF.7 2% - LB.1.3.1 / NL JN.1.11 + FLiRT [blues]: ½% - XEK 0% - KP.2.3 & KP.1.1.3 / LP Other [greys]: ⅖% - JN.1.16 ⅙% - other WHO-Vaccine-Target JN.1 0% - Other (not specified) † Dagger variants are not broken out by CDC, yet represent a significant share of recent GISAID sequences.
Public *
Rach(el) Against The Machine

well- another Trans Day of Visibility, another year in which the bulk of the trans community is still refusing to protect the disabled and chronically ill among us.

notice who isn't visible today. notice the friends and community members who have checked out of IRL meetups because the community is allowing airborne, contagious, disabling viruses to circulate without end.

and remember that we exist, too. we're here, and we're the ones who even you have forgotten.

#transdayofvisibility#WearAMask#CovidIsNotOver
Public
ahimsa

“Wake Up and Smell the C*VID: An evening without Eric Bogosian”: new play takes aim at NYC mask ban and more

thecanary.co/global/world-news

"As New York State’s budget deadline looms, so too does the specter of a proposed mask ban …"

"Wake Up and Smell the C*VID isn’t a typical play—it’s an intervention. A rupture. A refusal.

It refuses the erasure of an ongoing mass disabling event."

Canary · “Wake Up and Smell the C*VID: An evening without Eric Bogosian”: new play takes aim at NYC mask ban and more“Wake Up and Smell the C*VID: An evening without Eric Bogosian”: new play takes aim at NYC mask ban and more from Canary on 31 March 2025
#COVID#COVID19#LongCovid
Public
meduz'

I’m on day 3 of my first #COVID infection (probably caught at work), and already regreting having switched job 6 months ago from full remote to partial remote.

Fever, barely no sleep, coughing, throat pain when ingesting food, headache.

Wife also got it (from me, day 2), with migrains and vomits as bonus.

0/20 won’t recommend.

#CovidIsNotOver
Public
Ari Auntiefa 🏳️‍🌈🌞♾️

Someone asked me yesterday, "When was it that we came out of the pandemic?"

I replied, "Uh, we didn't."

They didn't like that.

I think what they meant was: When did the powers-that-be make us "return to normal" to save the economy? Because that's when they caught their first case of COVID (for which they are still physically paying). ☹️

#CovidIsNotOver
Public
trendless 🇨🇦 :flag_AB:

medrxiv.org/content/10.1101/20 (preprint)

Between November 2023 and March 2024, coastal Kenya experienced a new wave of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections detected through our continued genomic surveillance. Herein, we report the clinical and genomic epidemiology of SARS-CoV-2 infections from 179 individuals (total 185 positive samples) residing in the Kilifi Health and Demographic Surveillance (KHDSS) area (∼900 km2). Sixteen SARS-CoV-2 lineages within three sub-variants (XBB.2.3-like (58.4%), JN.1-like (40.5%) and XBB.1-like (1.1%)) were identified. Symptomatic infection rate was estimated at 16.0% (95% CI 11.1%-23.9%) based on community testing regardless of symptom status, and did not differ across the sub-variants (p = 0.13)

For most of the community surveillance positive cases, the infection episodes remained asymptomatic (n = 124, 83.2%)

medRxiv · Genomic and clinical epidemiology of SARS-CoV-2 in coastal Kenya: Insights into variant circulation, reinfection, and multiple lineage importations during a post-pandemic waveBetween November 2023 and March 2024, coastal Kenya experienced a new wave of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections detected through our continued genomic surveillance. Herein, we report the clinical and genomic epidemiology of SARS-CoV-2 infections from 179 individuals (total 185 positive samples) residing in the Kilifi Health and Demographic Surveillance (KHDSS) area (∼900 km2). Sixteen SARS-CoV-2 lineages within three sub-variants (XBB.2.3-like (58.4%), JN.1-like (40.5%) and XBB.1-like (1.1%)) were identified. Symptomatic infection rate was estimated at 16.0% (95% CI 11.1%-23.9%) based on community testing regardless of symptom status, and did not differ across the sub-variants ( p = 0.13). The most common infection symptoms in community cases were cough (49.2%), fever (27.0%), sore throat (7.3%), headache (6.9%), and difficulty in breathing (5.5%) and one case succumbed to the infection. Genomic analysis of the virus from serial positives samples confirmed repeat infections among five participants under follow-up (median interval 21 days, range 16-95 days); in four participants, the same virus lineage was responsible in both the first and second infections, while one participant had a different lineage in the second infection compared to the first. Phylogenetic analysis including >18,000 contemporaneous global sequences estimated that at least 38 independent virus introduction events occurred into the KHDSS area during the wave, the majority likely originating in North America and Europe. Our study highlights coastal Kenya, like most other localities, continues to face new SARS-CoV-2 infection waves characterized by the circulation of new variants, multiple lineage importations and reinfections. Locally the virus may circulate unrecognized as most infections are asymptomatic in part due to high population immunity after several waves of infection. Our findings highlight the need for sustained SARS-CoV-2 surveillance to inform appropriate public health responses such as scheduled vaccination for risk populations. Author summary Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has transitioned to an endemic respiratory pathogen causing seasonal outbreaks. We examined the epidemiological and genomic patterns of a wave of SARS-CoV-2 infections in coastal Kenya that occurred between November 2023 and March 2024. By analyzing genetic and epidemiological data from positive cases in Kilifi, we inferred the origins of the new strains, documented repeat infections and the virus’ ongoing evolution. Our data revealed several variants circulating in the community, indicating multiple new virus introductions probably before and during local outbreaks. Many infected individuals were asymptomatic, highlighting unnoticed transmission within the population. Despite low vaccination rates among the cases (∼7.0%), high population immunity has previously been reported locally. The common symptoms among those who were symptomatic included cough, fever, and sore throat. A few participants experienced repeat infections during the wave, often involving closely related strains. The virus lineages detected were most closely related to those sampled in Europe. Our findings emphasize that, despite the end of the emergency phase, SARS-CoV-2 remains a significant public health issue, necessitating ongoing monitoring and responsive measures e.g. target vaccinations, masking and good hygiene practices to protect those at risk of severe infection. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This research was funded by Wellcome through (a) a Career Development Award to CNA (Ref. #226002/A/22/Z & Ref. #226002/Z/22/Z) and (b) 226130/Z/22/Z from the Wellcome Covid19: understanding the biological significance of SARS CoV 2 variants application to IO. SD acknowledges support from the Fonds National de la Recherche Scientifique (F.R.S.FNRS, Belgium; grant nF.4515.22), from the Research Foundation, Flanders (Fonds voor Wetenschappelijk Onderzoek, Vlaanderen, FWO, Belgium; grant nG098321N), and from the European Union Horizon 2020 projects MOOD (grant agreement n874850) and LEAPS (grant agreement n101094685). E.C.H. is supported by a National Health and Medical Research Council (Australia) Investigator Grant (GNT2017197). AWL was supported by the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE) which is funded by the Science for Africa Foundation [Del22007] with support from Wellcome Trust and the UK Foreign, Commonwealth & Development Office and is part of the EDCPT2 programme supported by the European Union; the Bill & Melinda Gates Foundation [INV033558]; and Gilead Sciences Inc., [19275]. All content contained within is that of the authors and does not necessarily reflect positions or policies of any SANTHE funder. For the purpose of Open Access, the author has applied a CC-BY public copyright license to any author accepted manuscript version arising from this submission. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee/IRB of KEMRI Scientific Ethics and Research Unit (SERU), Nairobi Kenya gave ethical approval for this work. Each surveillance platform (community, outpatient, and inpatient) that provided samples analysed here had a dedicated research protocol. The protocols consenting and sample collection process were reviewed and approved by KEMRI Scientific Ethics and Research Unit (SERU), Nairobi Kenya (protocol numbers #3178, #3103 and 4724). Samples were collected following consent from a parent or guardian for participants aged <18 year olds (with assent for children aged between 13 to 18 year olds). Individual written informed consent was sought for participants aged >18 years. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes The final consensus genomes from the SARS-CoV-2 samples sequenced in this study have been deposited in the Global Initiative on Sharing all Influenza Data (GISAID) database and can be accessed at <https://doi.org/10.55876/gis8.250116pz>. Epidemiological data and scripts for data analysis are available on the Harvard dataverse <https://doi.org/10.7910/DVN/BMCJTI>.
#CovidIsNotOver
Public
Broadwaybabyto

I just had a guy get angry at me for saying we’re still in a pandemic. He said it was fear mongering and “silly” to continue to take precautions.

He then went on to say his wife has Long Covid and he’s had Covid “at least 4-5 times”.

This attitude is why we’re in this mess. His own wife was disabled by Covid, and rather than adapt his behaviour he’s exposed her 4-5 additional times.

Repeat infections are devastating to those with Long Covid. Not to mention each infection does cumulative damage, and eventually you will be left disabled.

Even if you’re someone who believes it’s “just a flu”… surely you recognize people didn’t get the flu 4-5 times in a four year period? Being sick that often is an aberration, and a darn good reason to take precautions.

You know who hasn’t had COVID 4-5 times? People who are taking precautions.

Bonus tip: If you’re masking and you become infected anyways, you’ve reduced your viral load AND you’ve made sure not to infect anyone else. That’s community care & compassion and it’s worth doing.

#covidisairborne#covidisnotover#longcovid
ExploreLive feeds
About